Meet Us
End-to-End CDMO
A wholly owned subsidiary of HiTeck Biopharma Technology, Inc., which was listed on the Shenzhen Stock Exchange in 2017.
Our Values
Integrity
Thankfulness
Professionalism
Progress
Our Philosophy
Reverence for Life
Safety First
Quality Always
On-Time Delivery
In 2017, HiTeck was listed on the main board of the Shenzhen stock exchange. Since that time, the HiTeck family of companies has grown to include HanKang Pharmaceutical Biotechnology in Tianjin and Weijia Pharma in Xiamen.
With an investment of over 150 Million USD, Hiray Pharma Solutions was launched in 2019 as an international end-to-end KSM+API CDMO with the vision to facilitate the development and manufacturing of important drug products and key intermediates around the world.
As an end-to-end CDMO, Hiray provides on-time, high-quality service for Process R&D, Analytical R&D, Production, and Quality Control. Hiray operates in strict compliance with, or exceeds, the latest standards for environment, health, and safety. Our commitment to protecting our environment and the health and safety of our staff is evident to everyone who enters our workplaces. Furthermore, Hiray is committed to absolute protection of our customers’ intellectual property. Hiray’s clients rest assured their project will be handled with integrity and skill, and their product will be delivered on-time.
MEET OURMANAGEMENT TEAM
Our Story
Our story began in 1992 with a small group of dedicated scientists who formed a pharmaceutical research organization on the campus of Wuhan University. Nestled among the university’s famous cherry blossoms, a modest laboratory gave birth to an extraordinary company, HiTeck Biopharma Technology. For eight years, researchers persevered to tackle the biopharmaceutical challenges of their day.
In 2000, investor and CEO, Max Chen, joined the team and led the organization to undertake the development of an effective dosage form of Nerve Growth Factor (NGF).
We are only given one chance at life, and every person has the right to enjoy a good life. We are innovating for life.
Max Chen, Founder & CEO
Although this potential drug to combat neurodegenerative disease had been discovered decades earlier by Nobel laureate Dr. Rita Levi-Montalcini, no one had yet discovered a way to safely deliver the drug to cells where it was needed.
After three years of research, the scientists of HiTeck Biopharma became the first in the world to develop an effective dosage form of NGF.
Later, HiTeck’s scientists developed the world’s first Tumor Necrosis Factor TRAIL drug to target receptors DR4 and DR5.
And in 2017, after years of success in the biopharmaceutical industry, HiTeck made a public offering and was listed on the Shenzhen stock exchange.
Not satisfied with their success in biological products alone, Max and his team led the company to expand its impact by investing in research and development of small molecule drug products. Hiray Pharma solutions was created in 2019 to address the need for the rapid development of drug products with small-molecular-weight active ingredients to treat the myriad of diseases confronting our world today. Accepting the baton from the HiTeck biopharma researchers who began nearly 30 years earlier, the scientists at Hiray are working tirelessly to safely deliver high-quality medicines that will improve the lives of people around the world.
Virtual Tour
Tour our beautiful new facility, located in the Sustainable Chemistry Zone of Jingmen, China.